Raymond James initiated coverage on Bausch Health with a new price target
$BHC
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $8.00 | Equal Weight | Barclays |
| 8/2/2024 | $9.00 → $3.00 | Neutral → Underweight | Piper Sandler |
| 7/10/2024 | $8.00 | Mkt Perform | Raymond James |
| 9/20/2023 | $9.00 → $16.00 | Hold → Buy | Jefferies |
| 6/16/2023 | Outperform → Market Perform | TD Cowen | |
| 7/29/2022 | Buy → Hold | Truist | |
| 7/29/2022 | $12.00 → $5.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/28/2022 | Overweight → Neutral | JP Morgan |
LAVAL, QC, Jan. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy (HE). While safe and well-tolerated, both clinical trials did not meet the primary endpoint. "We are disappointed in the results, as there is currently no approved treatment for these patients. We are currently reviewing the full dataset to determine potential new development opportunities," said Thomas J. Appio, Chief Executive Officer, Bausch Health. "We want to thank the patients, fam
LAVAL, QC, Jan. 21, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, February 18, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EST to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call. Conference Call Details Date: Wednesday, February 18, 2026Time: 5:00 p.m. U.S. ESTWebcast: http://ir.bauschhealth.com/events-and-presentations A replay of the conference call will be available on the investor rel
LAVAL, QC, Jan. 5, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Thomas J. Appio, Chief Executive Officer, will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 14, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website. Jean-Jacques (JJ) Charhon, EVP, Chief Financial Officer, and Jonathan Sadeh, M.D., EVP, Chief Medical Officer and Head of R&D will also be in attendance. Details Date: Wednesday, January 14, 2026 Time: 3:45 p.m. U.S. PT / 6:45 p.m. U.S. ET Webcast: http://ir.bauschhealth.com/events-and-presentations A replay of
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00
Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously
Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,
LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing
LAVAL, QC, Jan. 21, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, February 18, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EST to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call. Conference Call Details Date: Wednesday, February 18, 2026Time: 5:00 p.m. U.S. ESTWebcast: http://ir.bauschhealth.com/events-and-presentations A replay of the conference call will be available on the investor rel
Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t
SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)